By Miranda McLaren – Clinical Trials Alerts –
Mesenchymal stem cells have been explored across a wide range of diseases due to their potential to reduce inflammation and promote tissue repair and regeneration. BBG Advanced Therapies’ Rogelio Zamilpa, PhD takes us through the past, present, and future of these remarkable cells.
Dr. Zamilpa is the Executive Director of Biomanufacturing and Collaborative Programs at BBG Advanced Therapies, a subsidiary of BioBridge Global with extensive experience in stem cell research and manufacturing. Before joining BioBridge Global, Dr Zamilpa completed a post-doctoral training at UT Health San Antonio, during which he contributed to numerous publications on tissue repair and regeneration. Subsequently, he worked at a spin-off focused on developing manufacturing platforms for MSC expansion. He joined BBG Advanced Therapies’ biomanufacturing department in 2020 where he now supports industry partners with developing and manufacturing cell and tissue-derived products, which include MSCs.
